Your browser doesn't support javascript.
loading
Making Sense of Late Tissue Nodules Associated With Hyaluronic Acid Injections.
Goodman, Greg J; McDonald, Cara B; Lim, Adrian; Porter, Catherine E; Deva, Anand K; Magnusson, Mark; Patel, Anita; Hart, Sarah; Callan, Peter; Rudd, Alice; Roberts, Stefania; Wallace, Katy; Bekhor, Philip; Clague, Michael; Williams, Linda; Corduff, Niamh; Wines, Nina; Al-Niaimi, Firas; Fabi, Sabrina G; Studniberg, Howard M; Smith, Saxon; Tsirbas, Angelo; Arendse, Sean; Ciconte, Antoinette; Poon, Terence.
Affiliation
  • Goodman GJ; Honorary professor at the University College of London, London, United Kingdom.
  • McDonald CB; Dermatologist, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Lim A; Practicing dermatologist, Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Porter CE; Cosmetic physician in private practice in Sydney, New South Wales, Australia.
  • Deva AK; Professor, Department of Plastic and Reconstructive Surgery, Macquarie University, Sydney, Australia.
  • Magnusson M; Associate professor, Department of Plastic and Reconstructive Surgery, Griffiths University Southport, Queensland, Australia.
  • Patel A; Dermatologist in Private practice in Bondi Junction, New South Wales, Australia.
  • Hart S; Aesthetic physician in private practice in Auckland, the North Island, New Zealand.
  • Callan P; Specialist plastic surgeon in private practice in Geelong, Victoria, Australia.
  • Rudd A; Dermatologist, Department of Dermatology, Alfred Hospital Prahran Victoria, Victoria, Australia.
  • Roberts S; Aesthetic physician in private practice in Melbourne, Victoria, Australia.
  • Wallace K; Nurse practitioner at a private dermatology practice in South Yarra, Victoria, Australia.
  • Bekhor P; Dermatologist, Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Clague M; Cosmetic nurse in private practice in South Yarra, Victoria, Australia.
  • Williams L; Cosmetic physician in private practice in East Brisbane, Queensland, Australia.
  • Corduff N; Plastic surgeon in private practice in Geelong, Victoria, Australia.
  • Wines N; Principal dermatologist in private practice in Sydney, New South Wales, Australia.
  • Al-Niaimi F; Dermatologist, Department of Dermatology, Aalborg University, Aalborg, Denmark.
  • Fabi SG; Dermatologist, Department of Dermatology, University of California San Diego, La Jolla, CA, USA.
  • Studniberg HM; Dermatologist in private practice in Sydney, New South Wales, Australia.
  • Smith S; Dermatologist at the Sydney Clinical School, ANU Medical School, College of Health and Medicine, Australian National University, Canberra, ACT, Australia.
  • Tsirbas A; Oculoplastic surgeon in Sydney, New South Wales, Australia.
  • Arendse S; Cosmetic physician in private practice in Melbourne, Victoria, Australia.
  • Ciconte A; Dermatologist at Eastern Health Hospital, Box Hill and Canterbury, Victoria, Australia.
  • Poon T; Dermatologist in private practice in Sydney, New South Wales, Australia.
Aesthet Surg J ; 43(6): NP438-NP448, 2023 05 15.
Article in En | MEDLINE | ID: mdl-36759325
ABSTRACT

BACKGROUND:

The pathogenesis of delayed-onset tissue nodules (DTNs) due to hyaluronic acid (HA) injections is uncertain.

OBJECTIVES:

To formulate a rational theory for DTN development and their avoidance and treatment.

METHODS:

A multidisciplinary and multicountry DTN consensus panel was established, with 20 questions posed and consensus sought. Consensus was set at 75% agreement.

RESULTS:

Consensus was reached in 16 of 20 questions regarding the pathogenesis of DTNs, forming the basis for a classification and treatment guide.

CONCLUSIONS:

The group believes that filler, pathogens, and inflammation are all involved in DTNs and that DTNs most likely are infection initiated with a variable immune response. Injected filler may incorporate surface bacteria, either a commensal or a true pathogen, if the skin barrier is altered. The initially high molecular weight HA filler is degraded to low molecular weight HA (LMWHA) at the edge of the filler. Commensals positioned within the filler bolus may be well tolerated until the filler is degraded and the commensal becomes visible to the immune system. LMWHA is particularly inflammatory in the presence of any local bacteria. Commensals may still be tolerated unless the immune system is generally heightened by viremia or vaccination. Systemic pathogenic bacteremia may also interact with the filler peripheral LMWHA, activating Toll-like receptors that induce DTN formation. Given this scenario, attention to practitioner and patient hygiene and early systemic infection treatment deserve attention. Classification and treatment systems were devised by considering each of the 3 factors-filler, inflammation, and infection-separately.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cosmetic Techniques / Dermal Fillers Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Aesthet Surg J Year: 2023 Document type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cosmetic Techniques / Dermal Fillers Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Aesthet Surg J Year: 2023 Document type: Article Affiliation country: United kingdom